DESCRIPTION / INFORMATION
Bee venom therapy (BVT) is the deliberate use of honeybee venom in an attempt to treat disease or relieve symptoms. It has been practiced in various forms for centuries and is now used most often as a complementary therapy for pain and inflammatory or neurologic disorders. Venom may be delivered by live honeybee stings, injections of diluted or purified venom, or—in some studies—topical preparations.
Bee venom contains many biologically active substances, including melittin, phospholipase A₂, apamin, histamine, and other peptides, enzymes, and small molecules. Laboratory and animal studies have demonstrated numerous biological effects, including inflammatory, anti-inflammatory, immune, neurologic, antimicrobial, and cell-damaging actions. Whether these effects translate into useful treatments for particular human diseases is a separate question.
The major safety concern is allergic reaction, including potentially life-threatening anaphylaxis. Bee venom therapy must also be clearly distinguished from venom immunotherapy, an established medical treatment used by allergists to prevent severe allergic reactions to future insect stings.
These 20 questions explain what bee venom therapy is, what is known about its possible benefits, what the evidence does and does not show, how it differs from allergy treatment, and what risks and ethical considerations should be understood.
At a Glance: Bee Venom Therapy vs. Venom Immunotherapy
| Bee Venom Therapy (BVT) | Venom Immunotherapy (VIT) | |
|---|---|---|
| Purpose | Attempts to treat pain, inflammation, neurologic disease, or other conditions | Prevents serious allergic reactions to future insect stings |
| Primary patients | People seeking treatment for a non-allergic disorder | People with clinically significant insect-venom allergy |
| Evidence base | Limited and condition-specific | Strong; established allergy treatment |
| Standardized treatment? | No single standardized regimen | Yes; established build-up and maintenance protocols |
| Venom source | Live bee sting or prepared venom, depending on method | Standardized allergenic venom extract |
| FDA-recognized/approved use? | No FDA-approved bee venom therapy for arthritis, Parkinson’s disease, MS, pain, or similar disorders | FDA-licensed honeybee venom allergenic extracts are available for allergy diagnosis and immunotherapy |
| Main risk | Local reactions and systemic allergy, including anaphylaxis | Allergic reactions during treatment, managed within a medically supervised allergy program |
| Treatment setting | Varies widely | Medical allergy practice |
| Treatment goal | Symptom improvement or modification of another disease | Immunologic tolerance to future stings |
The distinction is crucial: evidence supporting venom immunotherapy does not establish that bee venom therapy is effective for unrelated diseases.
1. What is bee venom therapy?
Bee venom therapy is the intentional administration of venom from the Western honeybee, Apis mellifera, in an attempt to produce a therapeutic effect.
Methods have included:
- allowing live honeybees to sting selected locations;
- injecting diluted or purified bee venom;
- injecting venom at acupuncture points, often called bee venom acupuncture or pharmacopuncture; and
- using topical preparations containing bee venom.
BVT has been promoted for pain, arthritis, neurologic conditions, and other disorders.
However, the term describes a method of treatment, not an established indication. Evidence must be evaluated separately for each disease and each method of administration.
2. What is in bee venom, and how might its components work?
Bee venom is a complex mixture rather than a single drug.
Major components include:
Melittin — a 26-amino-acid peptide that makes up roughly 40–60% of dried bee venom. It can disrupt cell membranes and has numerous inflammatory and anti-inflammatory effects in experimental systems.
Phospholipase A₂ (PLA₂) — a major venom enzyme and an important honeybee-venom allergen. It acts on cell-membrane phospholipids and participates in inflammatory and immune effects.
Apamin — a small peptide that blocks certain calcium-activated potassium channels and has important effects on the nervous system.
Mast-cell-degranulating peptide — promotes release of substances such as histamine from mast cells.
Hyaluronidase — an enzyme that helps venom spread through tissue.
Bee venom also contains histamine, dopamine, noradrenaline, additional peptides, enzymes, amino acids, and other molecules. (Wehbe et al., 2019; Carpena et al., 2020)
These compounds can produce many effects in cells and experimental animals. Some appear anti-inflammatory under certain conditions, while others directly cause inflammation, pain, tissue injury, or allergic responses.
This apparent contradiction is important: a substance can have interesting pharmacologic effects without necessarily being an effective or safe treatment for disease.
3. What conditions has bee venom therapy been used or studied for?
BVT has been used or investigated for a broad range of disorders, especially:
- musculoskeletal pain;
- osteoarthritis;
- rheumatoid arthritis;
- low-back and neck pain;
- shoulder pain;
- neuropathic pain;
- Parkinson’s disease;
- multiple sclerosis;
- other neurologic conditions; and
- various inflammatory disorders.
Laboratory researchers have also studied bee-venom components for antimicrobial, antiviral, neuroprotective, and anticancer effects.
Those experimental findings should not be confused with established treatments.
A 2020 systematic review of randomized trials identified studies involving Parkinson’s disease, arthralgia, musculoskeletal disorders, and polycystic ovary syndrome, but emphasized the need for larger clinical trials. (Lee et al., 2020)
4. What does the scientific evidence show about effectiveness?
The answer differs according to the condition.
The evidence is strongest (not necessarily strong, but most developed) for some musculoskeletal pain conditions.
An updated 2025 systematic review identified 20 randomized controlled trials of bee venom acupuncture for musculoskeletal pain. Meta-analysis of small subsets found greater pain reduction with bee venom acupuncture than with saline-control injections in some comparisons.
However, the authors cautioned that:
- individual trials were small;
- relatively few studies could be combined statistically;
- disorders differed considerably;
- venom concentrations and doses varied; and
- clinical methods were heterogeneous.
They concluded that bee venom acupuncture appears promising but that the evidence remains insufficient for firm conclusions. (Lee et al., 2025)
The evidence for rheumatoid arthritis is weaker. A systematic review found only one eligible randomized trial and concluded that the evidence was too limited and low-quality to establish effectiveness. (Lee et al., 2014)
For Parkinson’s disease, small trials and a 2025 review report potentially favorable outcomes, but sample sizes remain small and treatment approaches vary. These findings are interesting but do not establish BVT as a standard Parkinson’s treatment.
Overall, BVT should be described as a biologically plausible but incompletely proven complementary therapy whose evidence varies by indication.
5. Is bee venom therapy the same as venom immunotherapy for bee-sting allergy?
No. They are fundamentally different treatments.
Venom immunotherapy (VIT) is an established allergy treatment for people at risk of serious systemic reactions from bee, wasp, hornet, or other Hymenoptera stings.
The patient receives carefully controlled injections of the relevant allergenic venom. The dose is gradually increased and then continued at a maintenance level to reduce the risk of a serious reaction if the person is stung again.
VIT has a well-established evidence base and is recommended by allergy specialists for appropriately selected patients. (Sturm et al., 2018)
Bee venom therapy, by contrast, attempts to use the biological effects of venom to treat some other condition, such as pain or Parkinson’s disease.
FDA lists standardized Apis mellifera honeybee venom among licensed standardized allergenic extracts. These products are part of allergy diagnosis and immunotherapy—not approval of BVT for arthritis, pain, MS, Parkinson’s disease, or another unrelated condition. (U.S. Food and Drug Administration, 2020)
6. How is bee venom therapy administered?
There is no single standardized method.
Live-bee-sting therapy
A live honeybee is held against the patient’s skin and allowed to sting. The stinger may sometimes remain in the skin for a prescribed period.
The amount of venom delivered is difficult to standardize precisely because it can vary with the bee and sting.
Bee venom injection
Purified or diluted venom may be injected in measured amounts. In bee venom acupuncture, injections are placed at traditional acupuncture points or other selected locations.
Topical products
Creams, ointments, gels, and other bee-venom-containing products have also been marketed or studied.
These routes should not automatically be treated as equivalent. A live sting, a measured injection, and a topical preparation can deliver very different amounts of venom and expose the immune system differently.
7. Is bee venom therapy safe?
BVT should not be described simply as “safe.”
Most reported reactions are local and relatively mild, including pain, redness, itching, and swelling.
However, bee venom is a powerful allergen capable of causing systemic allergic reactions and anaphylaxis.
A 2022 systematic review examined nearly 60,000 reported recipients of bee venom acupuncture and identified 27 episodes of anaphylaxis, which is an estimated incidence of about 0.045%, or roughly 4-5 episodes per 10,000 treated patients in the studies analyzed. (Ko et al., 2022)
That percentage is small, but anaphylaxis can be fatal.
The same review noted published deaths from anaphylaxis following bee venom acupuncture.
Risk therefore cannot be evaluated solely by asking whether adverse reactions are statistically uncommon. The severity of the possible event also matters.
8. What are the common side effects and serious risks?
Common reactions include:
- pain;
- burning or stinging;
- redness;
- itching;
- swelling; and
- local skin reactions.
Systemic reactions can include:
- widespread hives;
- generalized itching;
- facial or throat swelling;
- wheezing;
- difficulty breathing;
- abdominal symptoms;
- dizziness;
- falling blood pressure;
- loss of consciousness; and
- anaphylaxis.
Repeated exposure can also stimulate immune responses to bee-venom proteins.
Risk depends on many factors, including venom preparation, dose, route, previous exposure, individual immune characteristics, and the ability to recognize and treat a reaction immediately.
9. Who should not receive bee venom therapy, or who requires particular caution?
There is no scientifically validated universal contraindication checklist for experimental BVT.
However, known systemic allergy to honeybee venom is an obvious major concern. Deliberately exposing such a person to venom outside an allergist-supervised venom-immunotherapy program could provoke a dangerous reaction.
Particular caution is also warranted in people with:
- previous anaphylaxis;
- mast-cell disorders or other conditions associated with severe anaphylaxis;
- poorly controlled cardiovascular or respiratory disease;
- conditions that would make treatment of anaphylaxis particularly difficult; or
- medications that may complicate management of a severe allergic reaction.
The original draft lists beta-blocker therapy as a straightforward contraindication. That is now too categorical. Modern anaphylaxis guidance recognizes that beta-blockers and ACE inhibitors require individualized risk-benefit decisions even in people receiving medically necessary venom immunotherapy. (Golden et al., 2023)
Since BVT for non-allergic disease is experimental rather than medically established, there is generally less justification for accepting avoidable anaphylaxis risk.
Pregnancy, breastfeeding, and young age are also better described as situations in which adequate safety evidence for BVT is lacking, rather than as proven absolute contraindications.
10. Can allergy testing predict whether bee venom therapy will be safe?
Not reliably.
Skin testing or measurement of venom-specific IgE can help diagnose clinically suspected bee-venom allergy, particularly in someone who has already experienced a systemic sting reaction.
That does not make allergy testing a reliable screening tool that guarantees the safety of elective BVT.
A person may:
- have a negative test and later become sensitized;
- develop allergy after repeated treatment exposures;
- react despite previously tolerating venom; or
- have test results that do not perfectly predict the severity of a future reaction.
Importantly, the 2022 systematic review of bee venom acupuncture found no significant difference in reported anaphylaxis incidence between studies describing pre-treatment skin testing and studies in which such testing was not reported. (Ko et al., 2022)
Therefore, a negative skin test should never be interpreted as “this patient cannot have anaphylaxis.”
11. How much bee venom is given, and how many treatments are needed?
There is no universally accepted BVT dose or treatment schedule.
Published studies have used different:
- venom concentrations;
- injection volumes;
- treatment sites;
- numbers of injection points;
- treatment frequencies;
- durations; and
- methods of dose escalation.
Some protocols begin with a very small amount and progressively increase exposure. Others use fixed diluted doses.
This lack of standardization creates an important scientific problem.
If different investigators mean very different things by “bee venom therapy,” it becomes difficult to combine studies or determine:
- the optimal dose;
- whether there is a dose-response relationship;
- how long treatment should continue;
- how frequently it should be administered; or
- what dose provides the best balance between possible benefit and risk.
12. Is bee venom therapy FDA-approved?
The distinction between bee venom therapy and allergen immunotherapy is again essential.
FDA lists standardized Honey Bee Venom (Apis mellifera) allergenic extracts among licensed allergenic products used in the diagnosis and treatment of venom allergy.
That is not the same as FDA approving bee venom to treat:
- arthritis;
- musculoskeletal pain;
- multiple sclerosis;
- Parkinson’s disease;
- cancer; or
- other non-allergic conditions.
No FDA-approved BVT indication currently establishes bee venom as a standard treatment for those disorders.
Products marketed as creams, supplements, or complementary-health preparations also should not be assumed to have been demonstrated safe and effective for treating disease simply because they are commercially available.
13. Can bee venom therapy interact with medications or other treatments?
Potentially.
The most clinically important medication questions relate to the management of anaphylaxis.
Beta-blockers have historically raised concern because beta blockade can complicate responses to epinephrine and may influence the severity or treatment of anaphylaxis. ACE inhibitors have also been discussed as potential modifiers of risk.
Modern guidelines are more nuanced than simply declaring these medications forbidden. The 2023 anaphylaxis practice parameter recommends individualized decisions based on why the medication is needed and the risk of venom exposure. (Golden et al., 2023)
That guidance applies mainly to patients who need treatment for venom allergy, not to elective experimental BVT.
Patients considering BVT should disclose all:
- prescription medications;
- over-the-counter medicines;
- supplements;
- cardiovascular drugs;
- immune-modifying drugs; and
- allergy medications.
The draft mentions that some people take vitamin C with BVT. There is not sufficient evidence to recommend vitamin C as a routine safety measure or therapeutic enhancer, so I would omit that suggestion.
14. What should someone expect during and after a treatment session?
The immediate experience depends on the method used.
A live sting usually produces sharp pain followed by burning, redness, and swelling.
An injection of diluted venom may produce less intense local symptoms, depending on dose and concentration.
Local redness, swelling, itching, or discomfort may last for hours or longer.
However, the patient should also be observed for signs of a systemic reaction.
Warning signs include:
- widespread hives;
- swelling away from the treatment site;
- throat tightness;
- difficulty breathing;
- wheezing;
- dizziness;
- faintness;
- vomiting;
- sudden weakness; or
- falling blood pressure.
These symptoms require immediate medical assessment and, when anaphylaxis is suspected, prompt epinephrine treatment.
A severe allergic reaction should never be dismissed as an expected “healing response,” “detoxification reaction,” or evidence that the treatment is working.
15. How should someone evaluate a bee venom therapy practitioner?
Because BVT can cause anaphylaxis, practitioner selection involves more than asking how much experience someone has performing bee stings.
Important questions include:
- What professional health-care qualifications do you have?
- What training have you received specifically in bee venom therapy?
- What evidence supports using BVT for my particular condition?
- What form of venom do you use?
- How is the dose measured?
- What sterile technique is used for injections?
- How do you screen for contraindications?
- How do you recognize anaphylaxis?
- Is epinephrine immediately available?
- What other emergency equipment and medications are available?
- Is someone present who is trained to manage anaphylaxis?
- How long are patients observed after treatment?
- How are adverse reactions documented and reported?
- Will you communicate with my regular physician?
A practitioner who guarantees that testing makes anaphylaxis impossible, claims that severe allergic reactions are simply therapeutic reactions, or lacks immediate access to epinephrine should raise serious concern.
16. Is treatment with live bee stings the same as treatment with measured purified venom?
No.
Both expose a patient to honeybee venom, but there are important differences.
With a live sting, the exact venom dose is difficult to control. Venom delivered can vary according to the bee, how the sting occurs, and how long the stinger remains in place.
A prepared venom product can potentially offer:
- more reproducible concentration;
- measured dose;
- better characterization;
- control over sterility;
- standardized storage; and
- easier comparison among treatments.
Live-bee therapy also exposes the patient to the complete natural venom mixture rather than a selectively purified preparation.
These distinctions matter when interpreting research. Results from an injection study cannot automatically be extrapolated to live-bee-sting therapy.
Likewise, safety findings from a standardized preparation should not automatically be assumed to apply to poorly characterized venom products.
17. Can repeated bee venom therapy make someone allergic even if they were not allergic at the beginning?
Yes, that is possible.
Allergy is an immune response that can develop after exposure.
Someone who has tolerated previous bee stings or BVT sessions is therefore not guaranteed to remain non-allergic indefinitely.
Repeated venom exposure can stimulate production of venom-specific IgE in susceptible individuals. A systemic reaction may occur after earlier treatments produced only local reactions or no apparent reaction at all.
This is one reason that a single negative allergy test before beginning a long course of BVT cannot guarantee future safety.
The same principle is familiar in ordinary bee-sting allergy: people who experience anaphylaxis generally had previous exposures that did not necessarily produce the same severe reaction.
Every treatment session involving meaningful venom exposure therefore carries some continuing allergic risk.
18. If melittin and other venom compounds show anti-inflammatory or anticancer effects in the laboratory, doesn’t that prove bee venom therapy works?
No.
This is one of the most important concepts in interpreting BVT research.
Melittin, PLA₂, apamin, and other bee-venom components have many interesting effects in:
- test tubes;
- cultured cells;
- isolated tissues; and
- experimental animals.
For example, melittin can disrupt cell membranes and has demonstrated antimicrobial and anticancer effects under laboratory conditions. Bee-venom components can also influence inflammatory pathways.
But a laboratory effect does not tell us automatically:
- what dose is safe in a human;
- whether enough of the substance reaches the target tissue;
- whether the effect occurs at tolerable concentrations;
- whether whole bee venom behaves like the isolated component;
- whether treatment improves symptoms or survival; or
- whether benefits outweigh adverse effects.
Melittin illustrates this issue particularly well: the same membrane-disrupting property that makes it interesting as an experimental anticancer molecule also contributes to its toxicity and pain-producing effects.
Clinical effectiveness therefore requires appropriately controlled human studies, not simply demonstration of biological activity. (Carpena et al., 2020; Wehbe et al., 2019)
19. What emergency precautions are appropriate when bee venom is intentionally administered?
Because anaphylaxis can develop rapidly, emergency preparedness should exist before venom is administered.
At minimum, treatment settings should have:
- immediately available epinephrine;
- personnel who know how and when to administer it;
- the ability to assess breathing and circulation;
- a method to activate emergency medical services;
- appropriate observation after treatment; and
- a documented emergency-response plan.
Additional equipment appropriate to the clinical setting may include oxygen and supplies for airway and cardiovascular support.
Epinephrine is the first-line treatment for anaphylaxis. Antihistamines do not substitute for epinephrine when anaphylaxis is occurring.
Emergency preparation matters even when:
- the patient has tolerated previous treatments;
- allergy testing was negative;
- the dose is small; or
- no previous systemic reaction has occurred.
Anaphylaxis is uncommon, but its unpredictability and potential severity mean that deliberate venom administration should be planned accordingly. (Golden et al., 2023; Ko et al., 2022)
20. What about the welfare of the bees used in live-sting therapy?
Live-bee BVT raises an ethical issue that purified venom preparations do not raise in quite the same way.
A worker honeybee typically leaves its barbed stinger and part of the sting apparatus behind when it stings mammalian skin. The injury is usually fatal to the bee.
Thus, live-bee-sting therapy ordinarily results in the death of the individual bees used for treatment.
This should be acknowledged rather than treating the bee merely as a disposable delivery device.
Ethical consideration includes questions such as:
- Is killing live bees necessary when a measured venom preparation could accomplish the same therapeutic purpose?
- How are the bees housed and transported?
- Are they exposed to inappropriate temperatures, crowding, starvation, or other stress?
- How many bees are used during a treatment course?
- Is the claimed therapeutic benefit supported strongly enough to justify their use?
Bee-venom collection itself can also be performed using methods that stimulate bees to deposit venom onto a collection surface without necessarily killing them, allowing production of venom preparations without intentionally sacrificing a bee for each dose.
As with other forms of biotherapy, responsible practice should consider the welfare of both the patient and the therapeutic organism.
References
Carpena, M., Nuñez-Estevez, B., Soria-Lopez, A., Simal-Gandara, J., & others. (2020). Bee venom: An updating review of its bioactive molecules and its health applications. Nutrients, 12, 3360.
PubMed Central – free full text
Golden, D. B. K., Wang, J., Waserman, S., et al. (2023). Anaphylaxis: A 2023 practice parameter update. Annals of Allergy, Asthma & Immunology.
AAAAI – full practice parameter PDF
Ko, S.-H., et al. (2022). Incidence rate of bee venom acupuncture related anaphylaxis: A systematic review. Toxins, 14(4), 238. https://doi.org/10.3390/toxins14040238.
PubMed record
PubMed Central – free full text
Lee, J. A., Son, M. J., Choi, J., Jun, J. H., Kim, J.-I., & Lee, M. S. (2014). Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials. BMJ Open, 4, e006140. https://doi.org/10.1136/bmjopen-2014-006140.
PubMed record
PubMed Central – free full text
Lee, et al. (2025). Bee venom acupuncture for musculoskeletal pain conditions: An updated systematic review and meta-analysis. BMC Complementary Medicine and Therapies.
PubMed Central – free full text
Lee, et al. (2020). Clinical effectiveness and adverse events of bee venom therapy: A systematic review of randomized controlled trials. Toxins. PMID 32872552.
PubMed record
PubMed Central – free full text
Sturm, G. J., Varga, E.-M., Roberts, G., et al. (2018). EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy, 73(4), 744-764.
EAACI guideline page
U.S. Food and Drug Administration. (2020; current online listing). Injectable allergen extracts-Standardized. Honey Bee Venom (Apis mellifera) is listed among standardized venom products.
FDA standardized allergen extracts
Wehbe, R., Frangieh, J., Rima, M., El Obeid, D., Sabatier, J.-M., & Fajloun, Z. (2019). Bee venom: Overview of main compounds and bioactivities for therapeutic interests. Molecules, 24(16), 2997.
PubMed Central – free full text